Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Brontictuzumab||Phase I||Actionable||In a Phase I trial, Brontictuzumab (OMP-52M51) treatment in patients with advanced selected solid tumors was well-tolerated, demonstrated target engagement, and resulted in unconfirmed partial response in 5% (2/36) of patients (both adenoid cystic carcinoma with high NICD1 expression); stable disease (SD) in 28% (10/36), with 4 patients, all with high NICD1 expression, demonstrating SD for greater than 6 months; and a median progression-free survival of 65 days (PMID: 29726923; NCT01778439).||29726923|